FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 207 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI August 12, 2020 Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... January 30, 2026 New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo... September 13, 2019 Rare Disease Day 2026: Advancing equity for people living with rare... February 27, 2026 Load more HOT NEWS How will new cancer medicines be approved in the future? Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... EMA Recommends Granting a Marketing Authorisation for Equidacent Potential Clinical Utility of ctDNA-based Surveillance in Patients Treated with ICI
